In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Bruker (BRKR – Research Report). The ...

Stifel Nicolaus analyst Daniel Arias maintained a Hold rating on Bruker (BRKR – Research Report) today and set a price target of $57.00. The ...

Bruker Corp (BRKR) reports a 14.6% increase in Q4 revenue and sets optimistic guidance for 2025 despite challenges in Asia ...

Discover key takeaways from Bruker Corporation's Q4 2024 earnings call, highlighting strong diagnostics, semiconductor growth, and confident 2025 ...

Corporation reported its fourth-quarter 2024 earnings, surpassing analysts' expectations with an earnings per share (EPS) of $0.76 against the forecast of $0.74. Revenue also exceeded projections, ...

Scientific instrument company Bruker (NASDAQ:BRKR). reported Q4 CY2024 results exceeding the market’s revenue expectations, ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Clindamycin Phosphate Foam, 1%. Glenmark's Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to the ...

Bruker expects full-year earnings in the range of $2.67 to $2.72 per share, with revenue in the range of $3.47 billion to $3.54 billion. Bruker shares have fallen 12% since the beginning of the year.

Scientific instrument company Bruker (NASDAQ:BRKR). will be reporting results tomorrow before market hours. Here’s what ...

Bruker (NASDAQ:BRKR – Get Free Report) had its price target lowered by stock analysts at Barclays from $69.00 to $65.00 in a research note issued on Monday,Benzinga reports. The firm currently has an ...